John Valliant - Fusion Pharmaceuticals CEO Founder
Insider
John Valliant is CEO Founder of Fusion Pharmaceuticals
| Age | 53 |
| Phone | 289 799 0891 |
| Web | https://www.fusionpharma.com |
Fusion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2334) % which means that it has lost $0.2334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4711) %, meaning that it created substantial loss on money invested by shareholders. Fusion Pharmaceuticals' management efficiency ratios could be used to measure how well Fusion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Fusion Pharmaceuticals currently holds 50.33 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Fusion Pharmaceuticals has a current ratio of 17.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Fusion Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jasbir Seehra | Keros Therapeutics | 69 | |
| Ming Yin | Bolt Biotherapeutics | N/A | |
| Angela MD | Spero Therapeutics | N/A | |
| MBA MD | Ikena Oncology | 59 | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| Tommy Diraimondo | Janux Therapeutics | 39 | |
| Eric MD | Bioatla | 61 | |
| Sharon Goldbach | Harmony Biosciences Holdings | N/A | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Jay Short | Bioatla | 67 | |
| Peter Kushner | Olema Pharmaceuticals | 85 | |
| Kevin MBA | Bicycle Therapeutics | 57 | |
| Annie Neild | NewAmsterdam Pharma | N/A | |
| Simona King | Passage Bio | 52 | |
| Alfredo Castro | Ikena Oncology | N/A | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| John MBA | Harmony Biosciences Holdings | 57 | |
| Bryan Mcmichael | Coherus BioSciences | 46 | |
| Satyavrat CFA | Spero Therapeutics | 52 | |
| Gwen Carscadden | RAPT Therapeutics | 64 | |
| Dr B | Bicycle Therapeutics | 56 | |
Management Performance
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 |
Fusion Pharmaceuticals Leadership Team
Elected by the shareholders, the Fusion Pharmaceuticals' board of directors comprises two types of representatives: Fusion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fusion. The board's role is to monitor Fusion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Fusion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fusion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Leamon, Chief Officer | ||
| John Valliant, CEO Founder | ||
| Mohit Rawat, President Officer | ||
| Eric Hoffman, Senior Development | ||
| Dmitri MD, Chief Officer | ||
| Maria Stahl, Chief Officer | ||
| Victor Paulus, VP Affairs | ||
| Cara Ferreira, Chief Staff | ||
| Joanne Schindler, Executive Development | ||
| Eric Burak, Chief Officer | ||
| John CPA, Chief Officer | ||
| Amanda Cray, Senior Communications |
Fusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fusion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (54.04) % | |||
| Current Valuation | 1.69 B | |||
| Shares Outstanding | 85.06 M | |||
| Shares Owned By Insiders | 0.46 % | |||
| Shares Owned By Institutions | 86.80 % | |||
| Number Of Shares Shorted | 3.06 M | |||
| Price To Book | 8.13 X | |||
| Price To Sales | 874.50 X |
Pair Trading with Fusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to McKesson could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace McKesson when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back McKesson - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling McKesson to buy it.
The correlation of McKesson is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as McKesson moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if McKesson moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for McKesson can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |